Alexandra Hughes-Wilson - Sep 11, 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Patient Access and Commercial Planning
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Sep 11, 2024
Transactions value $
$0
Form type
4
Date filed
9/13/2024, 04:47 PM
Previous filing
Jun 27, 2024
Next filing
Sep 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $0 +40K +115.78% $0.00 74.5K Sep 11, 2024 Direct F1, F2
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $131K +93.3K +125.2% $1.40 168K Sep 11, 2024 Direct F1
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $75.8K +75K +44.67% $1.01 243K Sep 11, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Performance Based Restricted Stock Unit Options Exercise $0 -40K -100% $0.00 0 Sep 11, 2024 American Depository Shares 40K $0.00 Direct F1
transaction MREO Share Options (Right to buy) Options Exercise -$131K -93.3K -100% $1.40 0 Sep 11, 2024 American Depository Shares 93.3K $1.40 Direct F1, F3
transaction MREO Share Options (Right to buy) Options Exercise -$75.8K -75K -100% $1.01 0 Sep 11, 2024 American Depository Shares 75K $1.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.
F3 160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.
F4 240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.

Remarks:

Chief Patient Access and Commercial Planning